Screener
Minerva Neurosciences
NERVMinerva Neurosciences is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for central nervous system (CNS) diseases.
$166.4M+1,012%
Earnings
Next report
Nov 4, 2026 (in 2 months)EPS estimate-$0.14
Competitors
By market cap
By revenue growth
Profile
Minerva Neurosciences is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for central nervous system (CNS) diseases. The company's primary focus is addressing significant unmet medical needs in patients with schizophrenia, particularly the debilitating negative symptoms for which there are currently no approved treatments in the United States.
Competitive position
A clinical-stage developer of a potential first-in-class monotherapy for the negative symptoms of schizophrenia, currently navigating the FDA confirmatory trial process.
GeographiesUnited States, European Union, Latin America
Customer segmentsHealthcare systems, Psychiatric patients
Business modelR&D-stage biopharmaceutical, Licensing and royalties
SuppliersContract manufacturing organizations, Clinical research organizations, Raw material suppliers, Academic research institutions
CustomersSpecialized sales forces, Pharmaceutical distributors, Hospitals and psychiatric clinics, Third-party payors
CountryUnited States of America
Listed2014
Employees9.0
CEORemy Luthringer
SectorHealthcare
IndustryBiotechnology
Websiteminervaneurosciences.com
FilingsSEC EDGAR
FAQ
- What is Minerva Neurosciences's market cap?
- Minerva Neurosciences (NERV) has a market capitalization of $166.4M and trades on NASDAQ.
- Who are Minerva Neurosciences's competitors?
- Minerva Neurosciences's key competitors include Acadia Pharmaceuticals, Bristol-Myers Squibb, Cyclerion Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Minerva Neurosciences partner with?
- Minerva Neurosciences's notable partners include Tanabe Pharma Corporation, Janssen Pharmaceutica NV, Royalty Pharma plc, and others.
- What subsidiaries does Minerva Neurosciences have?
- Minerva Neurosciences's subsidiaries include Mind-NRG Sarl.
- Where is Minerva Neurosciences headquartered?
- Minerva Neurosciences is headquartered in United States of America and employs approximately 9 people. It has been publicly traded since 2014.